Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report suggests a focus on potential profit recovery and monitoring of key factors affecting profitability [1][3]. Core Views - The company's revenue for the first half of 2025 reached 1.866 billion yuan, a year-on-year increase of 37.32%, while the net profit attributable to shareholders was 134 million yuan, a decrease of 3.38% year-on-year [1]. - The second quarter of 2025 saw a revenue of 1.049 billion yuan, up 44.95% year-on-year, but the net profit attributable to shareholders was 52.67 million yuan, down 9.79% year-on-year [1][3]. - The company is experiencing short-term profit pressure due to changes in product structure and increased costs associated with the new production line in Zhoushan [3]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved total revenue of 1.866 billion yuan, with a year-on-year growth of 37.32%. The net profit attributable to shareholders was 134 million yuan, reflecting a decline of 3.38% year-on-year [1]. - For Q2 2025, the company reported revenue of 1.049 billion yuan, representing a 44.95% increase year-on-year, while the net profit attributable to shareholders was 52.67 million yuan, down 9.79% year-on-year [1][3]. Product and Project Developments - The Zhoushan production line is gradually coming online, contributing to significant revenue growth in Q2. The first phase of the "1 million tons corn deep processing health food ingredient project" has been completed and is in production [3]. - The company’s product mix has shifted, impacting gross margins, with Q2 gross margin at 16.56%, down 3.00 percentage points year-on-year [3]. Profitability Outlook - The report indicates that profit is under short-term pressure due to the impact of the Zhoushan project and the capitalization of convertible bond interest expenses. However, there is potential for profit recovery if the price of xylitol reverses and if production capacity utilization improves [3]. - The projected earnings per share (EPS) for 2025-2027 are 0.84, 1.23, and 1.73 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23X, 16X, and 11X [3].

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》（第 十四号—食品制造）相关规定，现将浙江华康药业股份有限公司（以下简称"公司"） 2025 年半年度主要经营数据公告如下： 一、2025 年半年度主要经营数据 1、按照产品类别分类情况 | | 单位：万元 币种：人民币 | | --- | --- | | 产品类别 | 2025 年半年度营业收入 | | 晶体糖醇产品 | 101,422.10 | | 液体糖、醇及其他产品 | 60,548.00 | | 其他 | 24,588.68 | | 合计 | 186,558.78 | 2、按照地区分类情况 | | 单位：万元 币种：人民币 | | --- | - ...

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting the company to clarify issues related to its construction projects and investment performance, particularly concerning the erythritol production project which has underperformed financially due to market conditions [1][2]. Summary by Sections Construction Projects and Investment - In 2024, the company invested 1.43 billion yuan in fixed assets, intangible assets, and other long-term assets, marking a 106.99% increase year-on-year. The fixed assets reached 2.25 billion yuan, up 45.13%, while construction in progress surged by 357.58% to 1.33 billion yuan, primarily due to the Zhoushan Huakang project [1]. - The erythritol production project generated revenue of 72.44 million yuan in 2024 but incurred a gross loss of 1.72 million yuan, continuing to fall short of initial projections since its trial operation began in May 2022 [1][2]. Erythritol Project Details - The total investment for the erythritol project is estimated at 350.41 million yuan, with cumulative investment reaching 362.68 million yuan by the end of 2024. The project aims to produce 30,000 tons of high-purity erythritol annually [5][6]. - In 2024, the company produced 6,834.50 tons of erythritol, achieving a sales rate of 97.96%. The market price for erythritol was approximately 13,000 yuan per ton by December 2024 [6][11]. Market Conditions and Competition - The erythritol market has faced significant challenges, including declining prices and increased competition, leading to a supply-demand imbalance. The price of erythritol has been under pressure since 2023, with some manufacturers exiting the market [7][11]. - The company noted that the market for erythritol was initially promising, but the influx of new competitors and expanded capacities led to a significant drop in prices, affecting profitability [7][11]. Inventory and Trade Business - By the end of 2024, the company's inventory reached 697 million yuan, a 147.26% increase year-on-year, primarily due to increased raw material reserves for the Zhoushan project. The raw materials accounted for 448 million yuan, up 385.15% [15][16]. - The cash flow from trade business payments was 1.15 billion yuan, reflecting a 198.58% increase, driven by the anticipated demand for corn from the Zhoushan project [15][16].